ALK inhibitors are potential anti-cancer drugs that act on tumours with variations of anaplastic lymphoma kinase (ALK) such as an EML4-ALK translocation.[

The global Anaplastic Lymphoma Kinase Inhibitors market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

North American market for Anaplastic Lymphoma Kinase Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Anaplastic Lymphoma Kinase Inhibitors is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global manufacturers of Anaplastic Lymphoma Kinase Inhibitors include Betta Pharmaceutcials Co., Ltd., Crtierium, Inc., F.Hoffman-La Roche Ltd., Helsinn Therapeutics, Novartis AG., Oncoethix GmbH, Pfizer, Inc., Takeda Pharmaceutical Co., Ltd. and Xcovery Holding Company, LLC, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Anaplastic Lymphoma Kinase Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anaplastic Lymphoma Kinase Inhibitors.

Report Scope

The Anaplastic Lymphoma Kinase Inhibitors market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anaplastic Lymphoma Kinase Inhibitors market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Anaplastic Lymphoma Kinase Inhibitors manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Anaplastic Lymphoma Kinase Inhibitors Market Report

Report Metric	Details
Report Name	Anaplastic Lymphoma Kinase Inhibitors Market
Segment by Type	Crizotinib Ceritinib Alectinib Hydrochloride
Segment by Application	NSCLC Breast Cancer Colorectal Cancer Neuroblastoma Ovarian Cancer Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Betta Pharmaceutcials Co., Ltd., Crtierium, Inc., F.Hoffman-La Roche Ltd., Helsinn Therapeutics, Novartis AG., Oncoethix GmbH, Pfizer, Inc., Takeda Pharmaceutical Co., Ltd., Xcovery Holding Company, LLC, Tesaro, Inc.
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anaplastic Lymphoma Kinase Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anaplastic Lymphoma Kinase Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Anaplastic Lymphoma Kinase Inhibitors Market report?

Ans: The main players in the Anaplastic Lymphoma Kinase Inhibitors Market are Betta Pharmaceutcials Co., Ltd., Crtierium, Inc., F.Hoffman-La Roche Ltd., Helsinn Therapeutics, Novartis AG., Oncoethix GmbH, Pfizer, Inc., Takeda Pharmaceutical Co., Ltd., Xcovery Holding Company, LLC, Tesaro, Inc.

What are the Application segmentation covered in the Anaplastic Lymphoma Kinase Inhibitors Market report?

Ans: The Applications covered in the Anaplastic Lymphoma Kinase Inhibitors Market report are NSCLC, Breast Cancer, Colorectal Cancer, Neuroblastoma, Ovarian Cancer, Others

What are the Type segmentation covered in the Anaplastic Lymphoma Kinase Inhibitors Market report?

Ans: The Types covered in the Anaplastic Lymphoma Kinase Inhibitors Market report are Crizotinib, Ceritinib, Alectinib Hydrochloride

1 Anaplastic Lymphoma Kinase Inhibitors Market Overview

1.1 Product Overview and Scope of Anaplastic Lymphoma Kinase Inhibitors

1.2 Anaplastic Lymphoma Kinase Inhibitors Segment by Type

1.2.1 Global Anaplastic Lymphoma Kinase Inhibitors Market Value Comparison by Type (2024-2030)

1.2.2 Crizotinib

1.2.3 Ceritinib

1.2.4 Alectinib Hydrochloride

1.3 Anaplastic Lymphoma Kinase Inhibitors Segment by Application

1.3.1 Global Anaplastic Lymphoma Kinase Inhibitors Market Value by Application: (2024-2030)

1.3.2 NSCLC

1.3.3 Breast Cancer

1.3.4 Colorectal Cancer

1.3.5 Neuroblastoma

1.3.6 Ovarian Cancer

1.3.7 Others

1.4 Global Anaplastic Lymphoma Kinase Inhibitors Market Size Estimates and Forecasts

1.4.1 Global Anaplastic Lymphoma Kinase Inhibitors Revenue 2019-2030

1.4.2 Global Anaplastic Lymphoma Kinase Inhibitors Sales 2019-2030

1.4.3 Global Anaplastic Lymphoma Kinase Inhibitors Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Anaplastic Lymphoma Kinase Inhibitors Market Competition by Manufacturers

2.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Manufacturers (2019-2024)

2.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Anaplastic Lymphoma Kinase Inhibitors Average Price by Manufacturers (2019-2024)

2.4 Global Anaplastic Lymphoma Kinase Inhibitors Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Anaplastic Lymphoma Kinase Inhibitors, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Anaplastic Lymphoma Kinase Inhibitors, Product Type & Application

2.7 Anaplastic Lymphoma Kinase Inhibitors Market Competitive Situation and Trends

2.7.1 Anaplastic Lymphoma Kinase Inhibitors Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Anaplastic Lymphoma Kinase Inhibitors Players Market Share by Revenue

2.7.3 Global Anaplastic Lymphoma Kinase Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Anaplastic Lymphoma Kinase Inhibitors Retrospective Market Scenario by Region

3.1 Global Anaplastic Lymphoma Kinase Inhibitors Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Anaplastic Lymphoma Kinase Inhibitors Global Anaplastic Lymphoma Kinase Inhibitors Sales by Region: 2019-2030

3.2.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales by Region: 2019-2024

3.2.2 Global Anaplastic Lymphoma Kinase Inhibitors Sales by Region: 2025-2030

3.3 Global Anaplastic Lymphoma Kinase Inhibitors Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Region: 2019-2030

3.3.1 Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Region: 2019-2024

3.3.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Region: 2025-2030

3.4 North America Anaplastic Lymphoma Kinase Inhibitors Market Facts & Figures by Country

3.4.1 North America Anaplastic Lymphoma Kinase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2019-2030)

3.4.3 North America Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2019-2030)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Anaplastic Lymphoma Kinase Inhibitors Market Facts & Figures by Country

3.5.1 Europe Anaplastic Lymphoma Kinase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2019-2030)

3.5.3 Europe Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Market Facts & Figures by Country

3.6.1 Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2019-2030)

3.6.3 Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Anaplastic Lymphoma Kinase Inhibitors Market Facts & Figures by Country

3.7.1 Latin America Anaplastic Lymphoma Kinase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2019-2030)

3.7.3 Latin America Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Market Facts & Figures by Country

3.8.1 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2019-2030)

3.8.3 Middle East and Africa Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2019-2030)

4.1.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2019-2024)

4.1.2 Global Anaplastic Lymphoma Kinase Inhibitors Sales by Type (2025-2030)

4.1.3 Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2019-2030)

4.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2019-2030)

4.2.1 Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2019-2024)

4.2.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Type (2025-2030)

4.2.3 Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Type (2019-2030)

4.3 Global Anaplastic Lymphoma Kinase Inhibitors Price by Type (2019-2030)

5 Segment by Application

5.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2019-2030)

5.1.1 Global Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2019-2024)

5.1.2 Global Anaplastic Lymphoma Kinase Inhibitors Sales by Application (2025-2030)

5.1.3 Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2019-2030)

5.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2019-2030)

5.2.1 Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2019-2024)

5.2.2 Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Application (2025-2030)

5.2.3 Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Application (2019-2030)

5.3 Global Anaplastic Lymphoma Kinase Inhibitors Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Betta Pharmaceutcials Co., Ltd.

6.1.1 Betta Pharmaceutcials Co., Ltd. Corporation Information

6.1.2 Betta Pharmaceutcials Co., Ltd. Description and Business Overview

6.1.3 Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Product Portfolio

6.1.5 Betta Pharmaceutcials Co., Ltd. Recent Developments/Updates

6.2 Crtierium, Inc.

6.2.1 Crtierium, Inc. Corporation Information

6.2.2 Crtierium, Inc. Description and Business Overview

6.2.3 Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Product Portfolio

6.2.5 Crtierium, Inc. Recent Developments/Updates

6.3 F.Hoffman-La Roche Ltd.

6.3.1 F.Hoffman-La Roche Ltd. Corporation Information

6.3.2 F.Hoffman-La Roche Ltd. Description and Business Overview

6.3.3 F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.3.4 F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Product Portfolio

6.3.5 F.Hoffman-La Roche Ltd. Recent Developments/Updates

6.4 Helsinn Therapeutics

6.4.1 Helsinn Therapeutics Corporation Information

6.4.2 Helsinn Therapeutics Description and Business Overview

6.4.3 Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Product Portfolio

6.4.5 Helsinn Therapeutics Recent Developments/Updates

6.5 Novartis AG.

6.5.1 Novartis AG. Corporation Information

6.5.2 Novartis AG. Description and Business Overview

6.5.3 Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.5.4 Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Product Portfolio

6.5.5 Novartis AG. Recent Developments/Updates

6.6 Oncoethix GmbH

6.6.1 Oncoethix GmbH Corporation Information

6.6.2 Oncoethix GmbH Description and Business Overview

6.6.3 Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Product Portfolio

6.6.5 Oncoethix GmbH Recent Developments/Updates

6.7 Pfizer, Inc.

6.6.1 Pfizer, Inc. Corporation Information

6.6.2 Pfizer, Inc. Description and Business Overview

6.6.3 Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Product Portfolio

6.7.5 Pfizer, Inc. Recent Developments/Updates

6.8 Takeda Pharmaceutical Co., Ltd.

6.8.1 Takeda Pharmaceutical Co., Ltd. Corporation Information

6.8.2 Takeda Pharmaceutical Co., Ltd. Description and Business Overview

6.8.3 Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Product Portfolio

6.8.5 Takeda Pharmaceutical Co., Ltd. Recent Developments/Updates

6.9 Xcovery Holding Company, LLC

6.9.1 Xcovery Holding Company, LLC Corporation Information

6.9.2 Xcovery Holding Company, LLC Description and Business Overview

6.9.3 Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Product Portfolio

6.9.5 Xcovery Holding Company, LLC Recent Developments/Updates

6.10 Tesaro, Inc.

6.10.1 Tesaro, Inc. Corporation Information

6.10.2 Tesaro, Inc. Description and Business Overview

6.10.3 Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Product Portfolio

6.10.5 Tesaro, Inc. Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Anaplastic Lymphoma Kinase Inhibitors Industry Chain Analysis

7.2 Anaplastic Lymphoma Kinase Inhibitors Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Anaplastic Lymphoma Kinase Inhibitors Production Mode & Process

7.4 Anaplastic Lymphoma Kinase Inhibitors Sales and Marketing

7.4.1 Anaplastic Lymphoma Kinase Inhibitors Sales Channels

7.4.2 Anaplastic Lymphoma Kinase Inhibitors Distributors

7.5 Anaplastic Lymphoma Kinase Inhibitors Customers

8 Anaplastic Lymphoma Kinase Inhibitors Market Dynamics

8.1 Anaplastic Lymphoma Kinase Inhibitors Industry Trends

8.2 Anaplastic Lymphoma Kinase Inhibitors Market Drivers

8.3 Anaplastic Lymphoma Kinase Inhibitors Market Challenges

8.4 Anaplastic Lymphoma Kinase Inhibitors Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Betta Pharmaceutcials Co., Ltd.

Crtierium, Inc.

F. Hoffman-La Roche Ltd.

Takeda Pharmaceutical Co Ltd

Xcovery Holding Company, LLC

Tesaro

List of Tables

Table 1. Global Anaplastic Lymphoma Kinase Inhibitors Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Anaplastic Lymphoma Kinase Inhibitors Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Anaplastic Lymphoma Kinase Inhibitors Market Competitive Situation by Manufacturers in 2023

Table 4. Global Anaplastic Lymphoma Kinase Inhibitors Sales (MT) of Key Manufacturers (2019-2024)

Table 5. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Anaplastic Lymphoma Kinase Inhibitors Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Anaplastic Lymphoma Kinase Inhibitors Average Price (USD/MT) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Anaplastic Lymphoma Kinase Inhibitors, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Anaplastic Lymphoma Kinase Inhibitors, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Anaplastic Lymphoma Kinase Inhibitors, Product Type & Application

Table 12. Global Key Manufacturers of Anaplastic Lymphoma Kinase Inhibitors, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Anaplastic Lymphoma Kinase Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anaplastic Lymphoma Kinase Inhibitors as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Anaplastic Lymphoma Kinase Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2019-2024) & (MT)

Table 18. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Region (2019-2024)

Table 19. Global Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2025-2030) & (MT)

Table 20. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Region (2025-2030)

Table 21. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Region (2019-2024)

Table 23. Global Anaplastic Lymphoma Kinase Inhibitors Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Region (2025-2030)

Table 25. North America Anaplastic Lymphoma Kinase Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2019-2024) & (MT)

Table 27. North America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2025-2030) & (MT)

Table 28. North America Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2019-2024) & (MT)

Table 32. Europe Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2025-2030) & (MT)

Table 33. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2019-2024) & (MT)

Table 37. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Sales by Region (2025-2030) & (MT)

Table 38. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Anaplastic Lymphoma Kinase Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2019-2024) & (MT)

Table 42. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2025-2030) & (MT)

Table 43. Latin America Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2019-2024) & (MT)

Table 47. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales by Country (2025-2030) & (MT)

Table 48. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Type (2019-2024)

Table 51. Global Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Type (2025-2030)

Table 52. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2019-2024)

Table 53. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Type (2025-2030)

Table 54. Global Anaplastic Lymphoma Kinase Inhibitors Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Anaplastic Lymphoma Kinase Inhibitors Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Type (2019-2024)

Table 57. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Type (2025-2030)

Table 58. Global Anaplastic Lymphoma Kinase Inhibitors Price (USD/MT) by Type (2019-2024)

Table 59. Global Anaplastic Lymphoma Kinase Inhibitors Price (USD/MT) by Type (2025-2030)

Table 60. Global Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Application (2019-2024)

Table 61. Global Anaplastic Lymphoma Kinase Inhibitors Sales (MT) by Application (2025-2030)

Table 62. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2019-2024)

Table 63. Global Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Application (2025-2030)

Table 64. Global Anaplastic Lymphoma Kinase Inhibitors Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Anaplastic Lymphoma Kinase Inhibitors Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Application (2019-2024)

Table 67. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Application (2025-2030)

Table 68. Global Anaplastic Lymphoma Kinase Inhibitors Price (USD/MT) by Application (2019-2024)

Table 69. Global Anaplastic Lymphoma Kinase Inhibitors Price (USD/MT) by Application (2025-2030)

Table 70. Betta Pharmaceutcials Co., Ltd. Corporation Information

Table 71. Betta Pharmaceutcials Co., Ltd. Description and Business Overview

Table 72. Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 73. Betta Pharmaceutcials Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Product

Table 74. Betta Pharmaceutcials Co., Ltd. Recent Developments/Updates

Table 75. Crtierium, Inc. Corporation Information

Table 76. Crtierium, Inc. Description and Business Overview

Table 77. Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 78. Crtierium, Inc. Anaplastic Lymphoma Kinase Inhibitors Product

Table 79. Crtierium, Inc. Recent Developments/Updates

Table 80. F.Hoffman-La Roche Ltd. Corporation Information

Table 81. F.Hoffman-La Roche Ltd. Description and Business Overview

Table 82. F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 83. F.Hoffman-La Roche Ltd. Anaplastic Lymphoma Kinase Inhibitors Product

Table 84. F.Hoffman-La Roche Ltd. Recent Developments/Updates

Table 85. Helsinn Therapeutics Corporation Information

Table 86. Helsinn Therapeutics Description and Business Overview

Table 87. Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 88. Helsinn Therapeutics Anaplastic Lymphoma Kinase Inhibitors Product

Table 89. Helsinn Therapeutics Recent Developments/Updates

Table 90. Novartis AG. Corporation Information

Table 91. Novartis AG. Description and Business Overview

Table 92. Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 93. Novartis AG. Anaplastic Lymphoma Kinase Inhibitors Product

Table 94. Novartis AG. Recent Developments/Updates

Table 95. Oncoethix GmbH Corporation Information

Table 96. Oncoethix GmbH Description and Business Overview

Table 97. Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 98. Oncoethix GmbH Anaplastic Lymphoma Kinase Inhibitors Product

Table 99. Oncoethix GmbH Recent Developments/Updates

Table 100. Pfizer, Inc. Corporation Information

Table 101. Pfizer, Inc. Description and Business Overview

Table 102. Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 103. Pfizer, Inc. Anaplastic Lymphoma Kinase Inhibitors Product

Table 104. Pfizer, Inc. Recent Developments/Updates

Table 105. Takeda Pharmaceutical Co., Ltd. Corporation Information

Table 106. Takeda Pharmaceutical Co., Ltd. Description and Business Overview

Table 107. Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 108. Takeda Pharmaceutical Co., Ltd. Anaplastic Lymphoma Kinase Inhibitors Product

Table 109. Takeda Pharmaceutical Co., Ltd. Recent Developments/Updates

Table 110. Xcovery Holding Company, LLC Corporation Information

Table 111. Xcovery Holding Company, LLC Description and Business Overview

Table 112. Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 113. Xcovery Holding Company, LLC Anaplastic Lymphoma Kinase Inhibitors Product

Table 114. Xcovery Holding Company, LLC Recent Developments/Updates

Table 115. Tesaro, Inc. Corporation Information

Table 116. Tesaro, Inc. Description and Business Overview

Table 117. Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Sales (MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)

Table 118. Tesaro, Inc. Anaplastic Lymphoma Kinase Inhibitors Product

Table 119. Tesaro, Inc. Recent Developments/Updates

Table 120. Key Raw Materials Lists

Table 121. Raw Materials Key Suppliers Lists

Table 122. Anaplastic Lymphoma Kinase Inhibitors Distributors List

Table 123. Anaplastic Lymphoma Kinase Inhibitors Customers List

Table 124. Anaplastic Lymphoma Kinase Inhibitors Market Trends

Table 125. Anaplastic Lymphoma Kinase Inhibitors Market Drivers

Table 126. Anaplastic Lymphoma Kinase Inhibitors Market Challenges

Table 127. Anaplastic Lymphoma Kinase Inhibitors Market Restraints

Table 128. Research Programs/Design for This Report

Table 129. Key Data Information from Secondary Sources

Table 130. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Anaplastic Lymphoma Kinase Inhibitors

Figure 2. Global Anaplastic Lymphoma Kinase Inhibitors Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Anaplastic Lymphoma Kinase Inhibitors Market Share by Type in 2023 & 2030

Figure 4. Crizotinib Product Picture

Figure 5. Ceritinib Product Picture

Figure 6. Alectinib Hydrochloride Product Picture

Figure 7. Global Anaplastic Lymphoma Kinase Inhibitors Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 8. Global Anaplastic Lymphoma Kinase Inhibitors Market Share by Application in 2023 & 2030

Figure 9. NSCLC

Figure 10. Breast Cancer

Figure 11. Colorectal Cancer

Figure 12. Neuroblastoma

Figure 13. Ovarian Cancer

Figure 14. Others

Figure 15. Global Anaplastic Lymphoma Kinase Inhibitors Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 16. Global Anaplastic Lymphoma Kinase Inhibitors Market Size (2019-2030) & (US$ Million)

Figure 17. Global Anaplastic Lymphoma Kinase Inhibitors Sales (2019-2030) & (MT)

Figure 18. Global Anaplastic Lymphoma Kinase Inhibitors Average Price (USD/MT) & (2019-2030)

Figure 19. Anaplastic Lymphoma Kinase Inhibitors Report Years Considered

Figure 20. Anaplastic Lymphoma Kinase Inhibitors Sales Share by Manufacturers in 2023

Figure 21. Global Anaplastic Lymphoma Kinase Inhibitors Revenue Share by Manufacturers in 2023

Figure 22. The Global 5 and 10 Largest Anaplastic Lymphoma Kinase Inhibitors Players: Market Share by Revenue in 2023

Figure 23. Anaplastic Lymphoma Kinase Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 24. Global Anaplastic Lymphoma Kinase Inhibitors Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 25. North America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Country (2019-2030)

Figure 26. North America Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Country (2019-2030)

Figure 27. U.S. Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 28. Canada Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 29. Europe Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Country (2019-2030)

Figure 30. Europe Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Country (2019-2030)

Figure 31. Germany Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. France Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. U.K. Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Italy Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 35. Russia Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 36. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Region (2019-2030)

Figure 37. Asia Pacific Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Region (2019-2030)

Figure 38. China Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. Japan Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. South Korea Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. India Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Australia Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Taiwan Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Indonesia Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Thailand Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 46. Malaysia Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 47. Philippines Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Latin America Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Country (2019-2030)

Figure 49. Latin America Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Country (2019-2030)

Figure 50. Mexico Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 51. Brazil Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 52. Argentina Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Sales Market Share by Country (2019-2030)

Figure 54. Middle East & Africa Anaplastic Lymphoma Kinase Inhibitors Revenue Market Share by Country (2019-2030)

Figure 55. Turkey Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 56. Saudi Arabia Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 57. U.A.E Anaplastic Lymphoma Kinase Inhibitors Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 58. Global Sales Market Share of Anaplastic Lymphoma Kinase Inhibitors by Type (2019-2030)

Figure 59. Global Revenue Market Share of Anaplastic Lymphoma Kinase Inhibitors by Type (2019-2030)

Figure 60. Global Anaplastic Lymphoma Kinase Inhibitors Price (USD/MT) by Type (2019-2030)

Figure 61. Global Sales Market Share of Anaplastic Lymphoma Kinase Inhibitors by Application (2019-2030)

Figure 62. Global Revenue Market Share of Anaplastic Lymphoma Kinase Inhibitors by Application (2019-2030)

Figure 63. Global Anaplastic Lymphoma Kinase Inhibitors Price (USD/MT) by Application (2019-2030)

Figure 64. Anaplastic Lymphoma Kinase Inhibitors Value Chain

Figure 65. Anaplastic Lymphoma Kinase Inhibitors Production Process

Figure 66. Channels of Distribution (Direct Vs Distribution)

Figure 67. Distributors Profiles

Figure 68. Bottom-up and Top-down Approaches for This Report

Figure 69. Data Triangulation

Figure 70. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Colon Cancer Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-31C5944

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global CAR T-Cell Immunotherapy Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-10J13802

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global Color Detection Sensors Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-6G9623

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global Appendix Cancer Treatment Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-2H1312

Mon Apr 15 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions